delta-Opioid receptor agonists as a therapeutic
approach in Parkinson's disease
by
Hill MP, Hille CJ, Brotchie JM.
Motac Neuroscience Ltd.,
Incubator Building, Grafton St.,
Manchester, UK.
Drug News Perspect. 2000 Jun;13(5):261-8

ABSTRACT

Current symptomatic treatments for Parkinson's disease are based largely on dopamine replacement therapies; however, the fact that these treatments are characterized by many long-term side effects has led to widespread interest in nondopaminergic therapies. To date, a nondopaminergic therapy with comparable efficacy to dopamine replacement has not been devised. Here the authors discuss recent findings that systemic administration of a selective delta-opioid receptor agonist has powerful antiparkinsonian effects in rodent and primate models of Parkinson's disease that are equivalent to those of dopamine replacement. delta-Opioid receptor agonists may prove to be useful for the symptomatic treatment of Parkinson's disease in humans.

Delta agonists
Learned helplessness
Enkephalinase inhibitors : RB801
Opioids, brain stimulation and reward
Cholecystokinin and delta opioid receptors
Delta opioid receptors, emotion and motivation
Delta-opioid receptor agonists as antidepressants?

Refs
and further reading

HOME
HedWeb
Nootropics
cocaine.wiki
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family